lidorestat (IDD 676) / Institute for Diabetes Discovery - LARVOL DELTA

Development and Exploration of Organic Compounds as Aldose Reductase Inhibitors: An Overview. (PubMed, Curr Top Med Chem) - "These include: i) derivatives of carboxylic acids (e.g., Epalrestat, Alrestatin, Zopalrestat, Zenarestat, Ponalrestat, Lidorestat, and Tolrestat); ii) derivatives of spirohydantoins and related cyclic amides (e.g., Sorbinil, Minalrestat, and Fidarestat); and iii) phenolic derivatives (e.g., related to Benzopyran- 4-one and Chalcone). This also describes the advancements made in ARI research and possible applications by obtaining the required data. The process involves thoroughly searching multiple databases-such as PubMed, ScienceDirect, and SciFinder-for citations."

Journal • Cardiovascular • Cataract • Diabetes • Diabetic Nephropathy • Metabolic Disorders • Ophthalmology • Renal Disease • Retinal Disorders • AKR1B1

Decoding selectivity: computational insights into AKR1B1 and AKR1B10 inhibition. (PubMed, Phys Chem Chem Phys) - "In this study, multiple computational strategies, including sequence alignment, structural comparison, Protein Contacts Atlas analysis, molecular docking, molecular dynamics simulation, MM-GBSA calculation, alanine scanning mutagenesis and pharmacophore modeling analysis were employed to comprehensively understand the selectivity mechanisms of AKR1B1/10 inhibition based on selective inhibitor lidorestat and HAHE. This study would provide substantial evidence in the design of potent and highly selective AKR1B1/10 inhibitors in future."

Journal • Addiction (Opioid and Alcohol) • Diabetes • Metabolic Disorders • Oncology • AKR1B1 • AKR1B10